advanced search

Pulmonary & Nasal Drug Delivery66

Issue No #66  April 18th, 2016


Download PDF


Inside the magazine

ENHANCING THE PERFORMANCE OF DRY POWDER INHALERS: BREATH ACTUATED MECHANISMS
PULMONARY
Alan Tweedie
Chiesi
ENHANCING THE PERFORMANCE OF DRY POWDER INHALERS: BREATH ACTUATED MECHANISMS
David Lewis and Alan Tweedie explain how BAMs work and present experimental data demonstrating their ability to control dose delivery.
PRODUCT SHOWCASE: DF30 WITH COCe: ULTRA-CLEAN, ROBUST & VERSATILE
RESPIRATORY
Aptar Pharma
PRODUCT SHOWCASE: DF30 WITH COCe: ULTRA-CLEAN, ROBUST & VERSATILE
Aptar Pharma’s new DF30 metering valve version incorporates a cyclic-olefincopolymer (COC) neck gasket to enhance its performance further. It is the result of continuous improvement to today’s worldleading DF30 technology platform.
COMPANY SHOWCASE: NOBLE
PULMONARY
Noble
COMPANY SHOWCASE: NOBLE
Noble®, the leader in onboarding and device training, is a full-service, patient-centred product development and manufacturing company.
SYSTEMS ENGINEERING FOR COMPLEX PORTABLE DRUG DELIVERY DEVICE DEVELOPMENT
PULMONARY
Bill Welch
Phillips-Medisize
SYSTEMS ENGINEERING FOR COMPLEX PORTABLE DRUG DELIVERY DEVICE DEVELOPMENT
Bill Welch explains how a systems-engineering approach provides an efficient method of developing smaller, smarter and more complex inhaler devices.
COMPANY SHOWCASE: NOVI
PULMONARY
Adam Smith
Copley Scientific
COMPANY SHOWCASE: NOVI
In December 2015 the inhaler automation specialists Novi Systems launched their latest product, a ten-way shake and fire system for pMDIs called DecaVertus. Novi continues to innovate, bringing efficiency, precision and repeatability to inhalation labs around the world.
IT’S JUST AN APP, ISN’T IT?
PULMONARY
Vaishali Kamat
Cambridge Consultants
IT’S JUST AN APP, ISN’T IT?
Vaishali Kamat and Jaquie Finn, outline some key questions that pharma companies should ask before embarking on the development of a connected health solution, and provide insights that could help companies make the most from their investment.
BIOEQUIVALENCE FOR NASAL SPRAYS: IMPORTANCE OF DEVICE PERFORMANCE
NASAL
Pascale Farjas
Nemera
BIOEQUIVALENCE FOR NASAL SPRAYS: IMPORTANCE OF DEVICE PERFORMANCE
Pascale Farjas describes the company’s Device Equivalence Program, which enables Nemera to preselect and propose an appropriate delivery system per identified drug to companies wishing to save time in their nasal spray development pipeline.
OPTIMAL SOLUTION FOR DIFFERENT INSPIRATIONAL RATES
PULMONARY
Dr Gabriela Dujovny
Qualicaps
OPTIMAL SOLUTION FOR DIFFERENT INSPIRATIONAL RATES
There is a wide range of devices available to deliver inhalation therapies, but there is increasing interest in the use of dry powder inhalers due to improved engineering and powder formulations. Gabriela Dujovny looks at the advantages and disadvantages of the DPIs currently available.
ADVANCES IN PULMONARY DELIVERY OF INHALED ANTI-INFECTIVES
PULMONARY
Dr David L Hava
Pulmatrix
ADVANCES IN PULMONARY DELIVERY OF INHALED ANTI-INFECTIVES
With the growing problems caused by antimicrobial resistance, there is increasing interest in the use of improved strategies for drug delivery. David L. Hava explores the benefits of nebulised inhaled antibiotics delivered via high throughput nebulisers for aqueous formulations or dry powder inhalations for cystic fibrosis patients.
FDA ISSUES FINAL GUIDANCE ON MEDICAL DEVICE HUMAN FACTORS STUDIES
RESPIRATORY
Dr Michael Gross
Chimera Consulting
FDA ISSUES FINAL GUIDANCE ON MEDICAL DEVICE HUMAN FACTORS STUDIES
Michael Gross and Adam Shames discuss US FDA draft recommendations on human factors validation which are part of the design validation requirement of device design controls.
Top